Purpose: Eslicarbazepine acetate (ESL) is indicated for treatment of focal epilepsy. Our aim was to evaluate the effect and tolerability of ESL in elderly and younger adults. The primary objective was to measure changes in seizure frequency before and after at least six months of treatment. Secondary objective was to analyse the safety profile. Sub-analysis was performed in patients previously treated with oxcarbamazepine. Method: A single-centre, retrospective study of patients with focal epilepsy treated with ESL. Data were collected by reviewing the clinical and laboratory files. Seventy-two patients received ESL, of which 14 were !60 years old, and were analysed for adverse effects. Fifty-nine patients received treatment for !6 months and were included in the evaluation of seizure frequency; in this group 12 were !60 years old. Results: Seizure frequency (n = 59) was reduced for both young adults (< 60 years) and elderly adults (!60); both groups achieved better seizure control from an average of 2 to 0.5 (p-value: 0.002) and 3.5 to 0.65 (p-value:<0.05) seizures per month, respectively. Adverse effects leading to treatment discontinuation (n = 72) were more frequent in elderly (42.9%) than in young adults (17.2%) (p-value 0.04). There was no significant difference in mild adverse effects between young (15.5%) and elderly adults (14.3%). Most common adverse effects were somnolence, gastrointestinal disturbances and dizziness. Conclusions: The study indicates that ESL has an advantageous profile in relation to seizure control. The discontinuation rate might be higher in elderly than in younger adults. Further prospective studies are needed to confirm these conclusions.
1. Introduction
Background and significance
Epilepsy is among the most significant chronic neurological diseases globally and has both major economic and non-economic implications. Focal-onset epilepsy has a prevalence in developed countries between 3 and 10 per 1000 [1, 2] affecting people of all ages, with highest prevalence among the elderly [3] .
The goals of epilepsy treatment are to achieve seizure freedom without significant adverse events, increase quality of life, and reduce morbidity and mortality. Seizure control has been achieved in around 70% of patients with appropriate anti-epileptic drug (AED) therapy in either mono-or polytherapy. The remaining 30% have inadequate seizure control with AEDs [4] , and around 25% experience significant adverse effects [5] .
Age is a major factor influencing the effect and tolerability of AEDs. The frequency of epilepsy due to progressive neurological disorders and focal epilepsies of unknown etiology increases with age and is associated with a poorer prognosis of epilepsy [6] . Furthermore drug-interactions in elderly taking concomitant medication may influence both the efficacy and tolerability of AEDs. Moreover, age-related changes in liver-and kidney function may also influence the pharmacokinetics and thereby the effect and adverse effects of AEDs.
Eslicarbazepine acetate (ESL) is one of the third generation AEDs that have been developed in the last ten years with a favorable safety profile [7, 8] . As data on using ESL in elderly patients is still limited, our intention in the present study was to evaluate ESL with a sub-analysis of elderly adults.
Eslicarbazepine acetate
Eslicarbazepine acetate is a novel once-daily voltage-gated sodium channel (VGSC) blockerindicated for treatment of focal epilepsy. Even though ESL belongs to the same dibenzoazepine family as carbamazepine (CBZ) and oxcarbazepine (OXC), it has different pharmacokinetic characteristics.
The ability to alter fast inactivation of VGSC characterised by CBZ and OXC is not shared by ESL, but similarly to Lacosamide it enhances the slow inactivation of VGSC [9] . Eslicarbazepine acetate is rapidly metabolized via a hydrolytic first-pass metabolism into almost exclusively its active component S-licarbazepine, which is better tolerated and able to cross the blood brain barrier more effectively than R-licarbazepine [10] . Oxcarbazepine is metabolized slower, both to its active S-licarbazepine and inactive R-licarbazepine (around 20-25%) which may cause adverse effects.
Eslicarbazepine acetate has enhanced inhibitory selectivity for rapid firing 'epileptic' neurons over those with normal activity [11] . In comparison with CBZ, ESL lacks the inhibitory effects upon K v 7.2 outward currents, which reduces ESLs ability to facilitate repetitive firing. And ESL has a 10-to 60-fold higher potency for blockade of low-and high affinity hCa v 3.2 inward currents, which enhances potential for antiepileptogenic effect [12] . An add-on effect of ESL to CBZ has been identified in patients whose CBZ treatment has failed [7] . Unlike CBZ, ESL is not inclined to autoinduction or enzyme induction. The elimination of ELS is renal (66%) and therefore dose adjustment is recommended for patients with renal impairment [13] .
Objective
Our aim was to evaluate the effect and safety profile of ESL in elderly and younger adults. The primary objective was to measure the change in seizure frequency before and after at least six months of treatment with ESL. Secondary objectives were to analyse the safety profile of ESL by evaluating the tolerability and serum sodium levels, as well as to evaluate seizure frequency and serum sodium levels in patients previously treated with OXC
Methods

Study design and subjects
This retrospective study covers patients with focal epilepsy treated with ESL at our clinic, a tertiary medical treatment centre for epilepsy. The clinical and paraclinical data were collected by reviewing the medical records of the patients. Data on previously used AEDs, the effective dose of ESL and its side effects were collected as well. Finally, concomitant medications were evaluated with emphasis on drugs that can cause hyponatremia.
Eslicarbazepine acetate was introduced either in mono-, or as an adjunctive therapy in patients with either uncontrolled epilepsy or unacceptable adverse effects to their previous AEDs, and the drug was up-titrated from 400 mg to the effective dose (max. 3000 mg). Patients were monitored at the clinic regularly, and their treatment was optimized as needed, in order to achieve sufficient seizure control.
Seventy-two patients were identified in our patient-registry treated with ESL between 2010 and 2015 (Fig. 1) . The patients were divided into two groups according to age: Younger Adults (YA) aged 20-59 years, n = 58, and Elderly Adults (EA) 60 years or older, n = 14. For the effect analyses both groups were further divided according to whether they received ESL for at least six months or more, i.e. patients "included"; Young Adults Included (YAI), n = 47, and Elderly Adults Included (EAI), n = 12. The patients who received ESL less than six months were not included in evaluation of efficacy, i.e. patient "excluded", Young Adults Excluded (YAE), n = 11 and Elderly Adults Excluded (EAE), n = 2.
Ethical considerations
The data were anonymized for the statistical analysis, and the study was approved by the Danish Data Protection Agency.
Data analysis
The effect analysis was carried out by comparing seizure frequencies in the YAI and EAI prior to and after at least six months of treatment with ESL. Seizure frequencies were registered in a patient self-administered seizure calendar.
The safety profile of ESL was evaluated based on the tolerability, i.e. self-reported adverse effects, and on the serum sodium levels. Adverse effects to ESL were registered for all patients receiving ESL independent of treatment duration. Serum sodium levels were examined by comparing levels prior to and after at least six months of treatment with ESL, but only for YAI and EAI. Information on sodium levels were missing for 13 out of 47 YAI and for one out of 12 EAI.
Statistical analysis
Data was evaluated assuming a significance level of a=0.05, and analysed by Wilcoxon signed ranks test or Mann-Whitney U test, since data was skewed or not following normal distribution. Binary variables were analysed by Chi-squared test, and samples less than five were analysed with Fisher's exact test.
Results
Descriptive data
The demographic and clinical baseline characteristics for all patients treated with ESL (n = 72) at our clinic are summarized in Table 1 . All patients had focal epilepsy with various etiology without major differences between the examined groups. There was a tendency towards lower treatment doses of ESL in EAI than in YAI, with an average of 1267 mg (median: 1200 mg) and 1515 mg (median: 1600 mg) respectively, but the difference was not significant (p-value: 0.17). The majority of patients (79.7%) was in polytherapy treatment. In YAI clobazam (n = 14), lamotrigine (n = 10), lacosamide (n = 10), and levetiracetam (n = 9) were the most frequently used drugs. In EAI the most frequently used drugs were levetiracetam (n = 4), lamotrigine (n = 3) and topiramate (n = 3), Table 2 .
Seizure control
We observed a significant decrease in seizure frequency for both YAI and the EAI treated with ESL. Results are summarized in Table 3 .
In the YAI-group seven patients were seizure free before ESL, six were so with treatment and one had in average 0.1 seizures per month (but had possible lack of compliance prior to the attack). Of the remaining 40 patients 12 (30%) achieved seizure freedom, 16 (40%) a !50% seizure reduction, eight (20%) an increase in seizure frequency and four (10%) experienced no change in seizure frequency with ESL.
In the EAI-group four patients were seizure free before and during use of ESL. Of the remaining eight, two (25%) achieved seizure freedom, two (25%) a !50% seizure reduction, three (38%) a 50% reduction in seizure frequency and one no change in seizure frequency with ESL.
The change in seizure frequencies was not significantly different between YAI and EAI (p-value: 0.54).
The difference in responder rate (defined as seizure reduction !50%) between YAI 28/40 (70%) and EAI 4/8 (50%) was not significant (p-value: 0.48) (Fig. 2) . Dose-related response was not observed in neither YAI nor EAI (n = 59) (Fig. 1). 
Tolerability
Tolerability was evaluated in all patients (n = 72) treated with ESL independent of treatment duration. ESL was well-tolerated without significant side-effects in 48/58 (82.8%) of the YA, and in 8/ 14 (57.1%) of the EA.
There was no significant difference (p-value: 0.19) between EA and YA in regards to the number of patients with any kind of adverse effects. Sub-analysis of adverse effects showed no significant difference (p-value: 0.91) between EA (2/14) and YA (12/47) in regards to mild to moderate adverse effects not leading to discontinuation, while there was a higher frequency of adverse effects leading to drug discontinuation in EA than in YA (p-value: 0.04).
Sodium
Sodium levels for the YAI and EAI are depicted in Table 3 . The median sodium level did not change significantly for YAI or for EAI on ESL, and it was not dose-related.
Fifteen patients (2 EAI and 13 YAI), that all received ESL in polytherapy either with other AEDs or other concomitant medications have developed hyponatremia (33.3% (15/45)). In six cases (40%) hyponatremia could be caused by other concomitant drugs such as citalopram, sertraline, furosemide, spironolactone or concomitant AED (CBZ), while explanation in nine patients (60%) is lacking. In these cases the most frequently used concomitant AEDs were levetiracetam and clobazam. One patient discontinued treatment due to hyponatremia. This was a 67-year old female, with severe hyponatremia (P-Na 121 mmol/L) that was already measured before introduction of ESL (Na 120 mmol/L), and it was reported as a probable side effect to previously use of OXC. However, this patient was on several concomitant medications i.e. sertraline, enalapril and hydrochlorothiazide, that could influence sodium levels.
OXC to ESL
A total of 26 patients from both groups (22 from the YAI group and four from EAI) had been using OXC prior to ESL. A significant seizure reduction was observed in both groups, even with lower average doses of ESL than the average doses OXC applied previously (Table 4 ). Fifteen of the 26 patients (58%) changed to ESL due to side-effects from OXC, thereof four due to hyponatremia. With ESL five (19%) patients had side effects from ESL. In Table 2 Patients in polytherapy treatment. Number of the patients receiving each antiepileptic drug is shown in the regards to hyponatremia sodium levels were normalized in two patients and two continued to have low sodium levels with ESL. One patient, that previously had normal sodium values with OXC, developed hyponatremia with ESL.
Discussion
This study demonstrated that ESL is an effective and welltolerated drug for seizure control in patients with uncontrolled epilepsy or unacceptable adverse effects to previous AEDs in both younger and older adults.
The reduction in seizure frequency was significant in both age groups. This finding corresponds with previous phase-III reports with ESL as adjunctive therapy, where the seizure frequency was significantly lower with both 800 mg and 1200 mg daily in three of the studies [8, 10, 14] and significantly lower with 1200 mg daily in one of the studies [15] . The responder rate was higher in our study (70% in YAI, 50% in EAI and 66% for YAI + EAI) than in the phase-III studies where responder rate was between 34 and 40% with 800 mg daily [10, 14] and 37-43% with 1200 mg daily [8, 10, 14, 15] . Other clinical reports confirms a noteworthy responders rate with ESL treatment [16] . Studies on ESL as monotherapy [17, 18] showed a responder rate between 31 and 36% with ESL 1200 mg daily and 42-48% with ESL 1600 mg daily. In our study there was no significant correlation between dose and response, which is different from previous reports [16] . There was a tendency towards a higher responder rate in YAI than EAI, which might be related to age, or lower doses of ESL in elderly.
Higher responder rate with ESL may be explained by its ability to enhance slow inactivation of VGSC and its ability to reduce firing frequencies of excitatory neurons. ESL may also inhibit the generation of a hyperexcitable network and inhibit seizure propagation from the focus therefore it provides antiepileptogenic effect [12] .
Dose-related side effects were not observed in our study. Similar to previous reports [16] the most frequent adverse effects were somnolence, dizziness and gastrointestinal disturbances. In the present study adverse effects leading to drug discontinuation were more frequent in elderly than in younger adults, the difference was significant, but due to small group sizes further investigations are needed to confirm our findings. The discontinuation rate in YA (17.2%) is in line with previous studies 8.2%-26.5% [10, 14] . A review of five phase-II studies on safety of ESL in elderly reported adverse effects in roughly 60%, which was not significantly different from adverse effects in non-elderly adults [19] .
Hyponatremia is often reported in patients using OXC with a discontinuation why rate of 7.1% [20] . Our study showed a higher incidence of asymptomatic hyponatremia (31%) in the patients treated with ESL compared to the literature data (1-12.5%) [16, 21] . However, the incidence of hyponatremia before initiating ESL treatment was 32% in our patients and no change in median serum sodium levels was observed when comparing them before and after ESL treatment. Our data can therefore not support a change from OXC to ESL on the indication of hyponatremia. All patients who developed hyponatremia were in polytherapy, either with other AEDs that do not affect sodium levels (except for one patient on CBZ) or with other concomitant drugs, which could cause hyponatremia. It is therefore still unclear whether any interactions between AEDs can somehow increase probability for hyponatremia, and given the limited study population in our study it is not possible to make further conclusions.
In our material, ESL was more effective in regards to seizure control than OXC in those patients who shifted from OXC to ESL. The expert recommended transition doses are 1:1 for OXC and ESL [21, 22] , but this is not in line with our observations as our patients in general needed lower doses for ESL than for OXC. It could be explained by its different mode of action. OXC alters fast inactivation of VGSC, while ESL enhances the slow inactivation of VGSC [9] .
Limitations
The limited sample size of patients treated with ESL either in mono-, or polytherapy and the retrospective study design are contributing factors to variation in the efficacy and tolerability. The short treatment period of 6 months may have negative influence on the effect due to temporary improvement in seizure frequency. In addition, we did not have the control group who were given OXC after failure with ESL as it is a retrospective study. Lastly, the subjects are a selected group of medically refractory patients with high seizure frequency and polypharmacy, and most of them had tried several AEDs before initiating of ESL, which makes generalisation of the results somewhat more difficult.
Conclusion
No significant difference was found in the efficacy of ESL in our retrospective analysis of two age groups, i.e. younger and elderly adults. Drug discontinuation due to adverse effects tended to be more frequent in elderly than in younger adults. Change to ESL from OXC did not change the occurrence of asymptomatic hyponatremia. Hyponatremia was not more frequent in the elderly adult group compared to the younger adults.
Our study supports the use of ESL in younger adults. In elderly ESL should be considered while keeping in mind that the discontinuation rate might be high. Further prospective studies are needed on ESL focusing on elderly, as age is the major influencing factor on the pharmacokinetic profile of AEDs.
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